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Patterns of daily human activity are controlled by
an intrinsic circadian clock that promotes 24 hr
rhythms in many behavioral and physiological pro-
cesses. This system is altered in delayed sleep phase
disorder (DSPD), a common form of insomnia in
which sleep episodes are shifted to later times mis-
aligned with the societal norm. Here, we report a he-
reditary form of DSPD associated with a dominant
coding variation in the core circadian clock gene
CRY1, which creates a transcriptional inhibitor with
enhanced affinity for circadian activator proteins
Clock and Bmal1. This gain-of-function CRY1 variant
causes reduced expression of key transcriptional
targets and lengthens the period of circadian molec-
ular rhythms, providing a mechanistic link to DSPD
symptoms. The allele has a frequency of up to
0.6%, and reverse phenotyping of unrelated families
corroborates late and/or fragmented sleep patterns
in carriers, suggesting that it affects sleep behavior
in a sizeable portion of the human population.INTRODUCTION
The circadian clock is an internal self-sustained oscillator that
operates in organisms’ tissues and cells to align recurrent daily
changes in physiology and behavior with 24-hr environmental
cycles. In humans, dysfunction or misalignment of the circadian
clock with environmental cues alters the timing of the sleep-
wake cycle, leading to a variety of circadian rhythm sleep disor-
ders (American Academy of Sleep Medicine, 2005). Delayed
sleep phase disorder (DSPD), which is characterized by a persis-
tent and intractable delay of sleep onset and offset times relative
to the societal norm, represents the most commonly diagnosed
type of circadian rhythm sleep disorder, with an estimated prev-
alence of 0.2%–10% in the general population (Zee et al., 2013).
The wide range of prevalence estimates reflects heterogeneity in
the manifestation of the disorder as well as variation in the strin-
gency with which clinical diagnosis criteria are applied (Sacket al., 2007; Weitzman et al., 1981). The pathophysiology of
DSPD remains obscure, with suspected causes including a dif-
ferential susceptibility of an individual’s circadian clock to envi-
ronmental entrainment cues such as the light/dark cycle and
altered properties of the oscillator itself that affect its period
length (Aoki et al., 2001; Campbell and Murphy, 2007; Chang
et al., 2009; Duffy et al., 2001; Micic et al., 2013).
The circadian clock is genetically encoded and susceptible to
modification by spontaneous or targetedmutation of the respec-
tive factors in animal models (Crane and Young, 2014; Lowrey
and Takahashi, 2011). In humans, rare genetic variations that
shorten circadian period are linked to familial advanced sleep
phase disorder (FASPD), a type of circadian rhythm sleep disor-
derwith habitual sleep timesearlier than the societal norm (Hirano
et al., 2016; Tohet al., 2001; Xuet al., 2005, 2007).Nocomparable
evidence has yet emerged for DSPD and the association of pro-
posed genetic polymorphisms with late chronotype, and DSPD
has remained controversial (Kripke et al., 2014). Yet, many clas-
sical twin studies have found a strong hereditary component to
chronotype preference in the range of 40%–50%, arguing for
an important role of genetic predisposition toDSPDetiology (Bar-
clay et al., 2010; Hur et al., 1998; Koskenvuo et al., 2007; Vink
et al., 2001). Here, we report a case of familial DSPD linked to a
dominant coding variation in cryptochrome circadian clock 1
(CRY1). This association is maintained in unrelated carrier fam-
ilies of theCRY1 variant. The studied allele encodes a CRY1 pro-
tein with an internal deletion, affecting its function as a transcrip-
tional inhibitor and causing lengthening of the circadian period.RESULTS
Characterization of Intrinsic Circadian Rhythmicity in
the DSPD Proband
The clinical diagnosis of DSPD in the proband, subject ‘‘TAU11’’
(female, aged 46), was based on a sleep history and diagnostic
interview, chronotype questionnaires, and actigraphy combined
with a sleep log (Figure 1A). To better characterize the intrinsic
circadian behavior, the subject completed an in-laboratory study
during which sleep and core body temperature were continu-
ously monitored (Figure 1B). The protocol consisted of a 2-day
entrainment period with habitual sleep times derived from the
sleep log. Entrained phase was determined by salivary dim lightCell 169, 203–215, April 6, 2017 ª 2017 Elsevier Inc. 203
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Figure 1. Circadian Behavior of Control Subject ‘‘TAU18’’ and the DSPD proband ‘‘TAU11’’
(A) Double-plotted home actigraphy records. Red and blue triangles indicate in-bed/out-of-bed times, respectively, according to sleep logs. Asterisks indicate
Sundays.
(B) In-laboratory protocol: entrainment conditions on the first 4 days with sleep-log-based, habitual sleep times on entrainment days (EN) 1 and 2 and enforced
times in bed from 23:00 to 7:00 on EN3 and 4. Saliva samples for DLMO estimation were collected beginning at 18:00 on EN1 every 30min until bedtime. From the
fifth day on until the end of the study (free-run days FR1–14), subjects were kept under time-isolation conditions with instructions to sleep whenever so inclined.
Polysomnographic (PSG) sleep and core body temperature were recorded continuously throughout the study.
(C) Double-plotted sleep/wake behavior during the in-laboratory study. Colors denote sleep stage derived from PSG records (N1, turquoise; N2, green; N3, blue;
REM red). Gray areas indicate periods of missing PSG data during log-based time in bed. On the first and last study days, gray shading marks the beginning and
end of data acquisition. Arrow denotes DLMO. Asterisk denotes the beginning of the free-run.
(D) Analysis of sleep rhythmicity. Circadian rhythm parameters during the free-run were analyzed by X2 periodogram and fast Fourier transform (FFT) analysis,
which yielded period and amplitude, respectively.
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melatonin onset (DLMO) on the second entrainment night. This
was followed by 2 days of enforced time in bed from 23:00 to
7:00. At the end of the 4-day entrainment interval, the subject
entered a 14-day period of time isolation during which sleep
was permitted whenever so inclined (free-run).
Compared to a control subject of normal chronotype under-
going the same protocol, several circadian abnormalities were
apparent in the proband: consistent with a phase delay, en-
trained DLMO occurred at 2:32, well after the time expected in
a subject of normal chronotype (typically between 20:00 and
22:00) and closer to the time of habitual sleep onset (Figure 1C)
(Chang et al., 2009; Molina and Burgess, 2011). Sleep during the
free-run was highly variable both in the timing and the duration
of major sleep periods, consistent with at-home actigraphy
and sleep-log records (Figures 1A and 1C). The resulting gross
sleep/wake rhythm had a period of 24.5 hr with noticeably damp-
ened amplitude (Figure 1D). By contrast, the 24.2-hr period
length of a control subject undergoing the same protocol
matches the intrinsic period length reported for normal human
subjects (Czeisler et al., 1999). Aberrant rhythmicity in the sleep
behavior of TAU11 was mirrored by the pattern of core body
temperature oscillations in which a long-period rhythm of
24.8 hr and diminished amplitude were even more pronounced
(Figures 2A–2C and S1). The phenotypic concordance of the
different circadian measures strongly argues for the presence
of an intrinsic circadian rhythm disorder in the proband.
Identification of CRY1 c.1657+3A>C as a Candidate
DSPD Allele
To identify the cause of circadian dysfunction in the proband, we
performed candidate sequencing of genes that form the circa-
dian clock in mammals. The core molecular clock consists of a
negative-feedback loop in which the activity of the transcription
factors Clock and Bmal1 (called ARNTL in humans) is repressed
by the products of its target genes of the Per and Cry family,
creating a cycle that takes 24 hr to complete (Figure 3A). In
this complex process also involving regulation of post-transla-
tional modification and nuclear translocation, Cry1 is commonly
recognized as the main transcriptional repressor of Clock and
Bmal1 (Anand et al., 2013; Griffin et al., 1999; Kume et al.,
1999; Oster et al., 2002; van der Horst et al., 1999; Vitaterna
et al., 1999; Ye et al., 2014). By contrast, the mechanism of
action of the Per proteins appears to be more variable, ranging
from indirect repression through recruitment of generic chro-
matin modifiers to in fact promoting transcriptional de-repres-
sion (Chiou et al., 2016; Duong et al., 2011; Duong and Weitz,
2014). Our candidate gene sequencing identified an adenine-
to-cytosine transversion within the 50 splice site following exon
11 in one allele of the proband’s CRY1 gene (Figures 3B and
3C). Given usual conservation of the +3 position as a purine,
this change is expected to cause splice site disruption and
exon skipping (King et al., 1997). To test for a resulting coding
change, we amplified part of the CRY1 cDNA encompassing
exon 11 from a primary dermal fibroblast cell line derived from
the proband. Indeed, an additional product corresponding to
the expected D11 size was present in the proband’s sample,
but not in those derived from 18 other unrelated subjects
(Figure 3D). With a size of 72 base pairs, exon 11 skipping ispredicted to cause an in-frame deletion of 24 residues in the
C-terminal region of the CRY1 protein, and a matching, higher-
mobility band was specifically detected in protein extracts
from the proband cell line (Figure 3E).
Given the prominent role of CRY1 in the mammalian clock, we
postulated that the circadian abnormalities in the proband were
related to the observed modification of CRY1. To test this hy-
pothesis, we obtained information on sleep patterns from mem-
bers of the proband’s family and genotyped them for presence or
absence of the candidate allele. Delayed sleep behavior was
found to be common among male and female family members
and across several generations, consistent with an autosomal-
dominant inheritance pattern (Figures 4A and S2; Table S1).
Presence of the CRY1 c.1657+3A>C allele segregated with de-
layed sleep timing, with the exception of one carrier (TAUX08),
who reported a history of persistent sleep problems but was
complaint free at the time of study, on an occupationally required
very early routine that was purposely maintained on free days
(see Table S1 for details).
In a complementary approach, we also performed an
unbiasedsearch for genetic variants co-segregatingwith aberrant
sleep behavior in the proband kindred through whole exome
sequencing of additional family members (three affected, one un-
affected). Amongvariantswithminor allele frequenciesbelow1%,
which are common to all affected subjects, but not the unaffected,
and which are predicted to affect protein coding, the candidate
CRY1 allele was the only variant affecting a gene with a known
or implicated role in the regulation of sleepor circadian rhythmicity
(Table S2). Also, although some additional more common clock-
gene variants were also present in the original proband TAU11,
none of these segregated with sleep behavior in the family (see
Methods Details). These results point to the CRY1 c.1657+3A>C
allele as a strong candidate-genetic variant for familial DSPD.
Reverse Phenotyping of SleepBehavior in Heterozygous
and Homozygous Carriers of the CRY1 c.1657+3A>C
Allele from an Unrelated Population
In databases of human genetic variation, the candidate CRY1
allele has a frequency of up to 0.6% (rs184039278: minor allele
frequency 0.0012 in 1000 Genomes, 0.004335 in ExAC total
with 0.006537 in non-Finnish Europeans). This frequency lies
within the reported range of DSPD prevalence (Zee et al.,
2013) and is high enough to attempt the identification of addi-
tional carriers consenting to a characterization of their sleep
behavior through a reverse-phenotyping approach (Özçelik
and Onat, 2016). In genomic databases of the Turkish popula-
tion, we identified 28 carriers of the CRY1 c.1657+3A>C allele,
including one homozygous individual. Of these, investigation of
sleep behavior through questionnaires and personal interview
was possible in six unrelated families (DSPD-1, -2, -4, -6, -7,
-9, and -14) totaling 70 subjects (8 homozygous carriers, 31 het-
erozygous carriers, 31 non-carriers) (Figure 5 and Table S1).
Subjects also provided a DNA sample to determine the CRY1
allele status. Aberrant sleep behavior was reported by 38 car-
riers, but not by their non-carrier relatives or spouses, indicating
a very high penetrance of CRY1-related sleep disturbance
consistent with the original proband family. In addition to late







DSPD Subject TAU11Control Subject TAU18
Figure 2. Core Body Temperature of Control Subject ‘‘TAU18’’ and the DSPD proband ‘‘TAU11’’
(A) Double-plotted core body temperature during the in-laboratory study. The scale of the y axis for each individual study day is 2.3C. Data shown as gray fill are
interpolated from raw data shown as black dot overlay (see STARMethods for details). Red asterisk in the DSPDproband denotes the beginning of the free-run. In
the control subject, the indicated free-run start time corresponds to the time used for analysis of rhythmicity and differs from the actual free-run start time due to a
preceding 12-hr gap in the temperature record.
(B) Double-plotted sub-mean core body temperature. Themean temperature of the entire data series was calculated from outlier-corrected, interpolated data for
each subject, and data points below the mean are plotted as black fill.
(C) Analysis of core body temperature rhythmicity. Circadian rhythmicity during the free-run was analyzed by X2 periodogram and FFT analysis to measure period
and amplitude, respectively.
See also Figure S1.sleep consisting of a brief sleep period early in the night and
extended naps during the day. Fragmented sleep was particu-
larly prevalent among those carriers for whom early rising was
a necessity due to cultural or social obligations. Of note, no dif-
ference in sleep behavior was observed between heterozygous
and homozygous carriers of the CRY1 allele, consistent with an
autosomal-dominant mode of inheritance. The one carrier with
reported conventional sleep times (DSPD-6 16-068) was subject
to work-imposed strong light exposure, raising the possibility
that the CRY1-mediated disposition can be modifiable given206 Cell 169, 203–215, April 6, 2017adequate environmental conditions. Nevertheless, there was a
very strong association between CRY1 allele status and sleep
behavior in the reverse-phenotyped families and the original pro-
band kindred (Fisher’s exact p < 0.0001, odds ratio = 1,928, 95%
confidence interval 76–48,904).
CRY1 Exon 11 Deletion Affects Circadian Clock Cycling
and CRY1 Molecular Function
To directly test whether the deletion of exon 11 of CRY1 affects





A Figure 3. Mutation of CRY1
(A) The core molecular circadian clock in mam-
mals. Transcriptional activity of Clock and Bmal1
leads to expression of Per and Cry family genes,
whose products undergo posttranslational modi-
fication, translocate to the nucleus, and inhibit
Clock/Bmal1-mediated transcription with Cry1
acting as the main repressor.
(B) Exon organization of the human CRY1 gene
with the encoded protein regions shown above.
Box represents the region enlarged in (C). Arrows
indicate primer binding sites used in (D).
(C) Primary sequencing trace of the region
immediately following exon 11 in the proband’s
genomic DNA (left) and schematic diagram de-
picting the expected consequences of the A-to-C
transversion on CRY1 mRNA splicing (right).
(D) RT-PCR analysis of the CRY1 mRNA between
exons 10 and 13. Samples 03 to 21 are amplified
from primary fibroblast cell lines from 19 different
subjects, with number 11 belonging to the pro-
band. Controls on the right are amplified from
clonedCRY1 full-length and D11 cDNA. Expected
product sizes are indicated.
(E) CRY1 protein expression in the 19 subject-
derived fibroblast cell lines. TUBULIN levels are
shown as a loading control.expressed CRY1 form. Human full-length or CRY1 D11 variants
were expressed in CRY1/2 double-deficient mouse embryonic
fibroblasts (DKO MEFs) using regulatory elements previously
characterized to recapitulate endogenous CRY1 oscillation
(Ukai-Tadenuma et al., 2011). As expected, CRY1 expression
restored circadian cycling of a Bmal-luciferase reporter in previ-
ously arrhythmic DKO MEFs, albeit with a long period, as previ-
ously described for this experimental system (Khan et al., 2012)
(Figure 4B). Compared to full-length CRY1, expression of the
D11 form increased circadian period by approximately half an
hour, similar to the phenotype observed in the proband. The ef-
fect was not due to differences in the amounts of the ectopically
expressed CRY1 forms (Figure 4B). In contrast to CRY1, expres-
sion of CRY2 in CRY DKO MEFs did not restore their circadianrhythmicity, consistent with previous
reports (Khan et al., 2012), and the
differential period length between the
two CRY1 forms was still observed in its
presence (Figure S3A). These results
demonstrate a direct effect of CRY1
exon 11 deletion on circadian period
length, which matches DSPD symptoms.
The Cry1 protein consists of a
conserved photolyase homology region,
which mediates transcriptional repres-
sion of Clock/Bmal1, a C-terminal helix
previously described as a predicted
coiled coil, which interacts with Per2
and Fbxl3 in a mutually exclusive manner
and a C-terminal extension also referred
to as the ‘‘tail’’ (Figures 3B and S3B)(Chaves et al., 2011; Merbitz-Zahradnik and Wolf, 2015). The
Cry1 tail region represents the most poorly conserved and least
functionally and structurally characterized region of the protein.
It has been shown to affect Cry1 nuclear translocation, to interact
with the Bmal1 transactivation domain possibly in an acetylation-
dependent fashion, and to bephosphorylated in amanner that in-
volves regulation by DNA-PK (Chaves et al., 2006; Czarna et al.,
2011; Gao et al., 2013; Hirayama et al., 2007; Xu et al., 2015).
Interestingly, the tail is not essential to Cry1’s ability to restore
circadian cycling to arrhythmic DKO MEFs but does modulate
the period length and amplitude of the resulting oscillation
(Khan et al., 2012; Li et al., 2016). Overall, current evidence points
to a regulatory role of theCry1 tail in the transcriptional repression
complex involving Clock, Bmal1, and possibly other factors atCell 169, 203–215, April 6, 2017 207
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Figure 4. Effect of the CRY1 Mutation on
Human Sleep Timing and Clock Oscillation
(A) Segregation of the CRY1 c.1657+3A>C allele
with delayed sleep in the proband’s family. Ge-
notype is shown inside symbols. Color code and
symbols are explained in the legend. Numbers
represent midsleep point on free days (MSF)
(Roenneberg et al., 2003). See also Table S1 for
details.
(B) Deletion of CRY1 exon 11 affects circadian
period length. CRY1 fl or D11 cDNAs were ex-
pressed in Bmal1-luc DKO MEFs using a lentiviral
expression system that preserved the regulatory
elements necessary to recapitulate endogenous
CRY1 expression. Cells were synchronized with
20 mM forskolin, and bioluminescence output
was recorded for 7 days. Traces show average
detrended bioluminescence counts normalized
to the first peak for each genotype (CRY1 fl
blue, CRY1 D11 red). Period was calculated from
bioluminescence recordings of quadruplicate
samples from quadruplicate CRY1 infections
(circles, fl 1–4; diamonds, D 1–4). Data from
three independent experiments are shown (gray
shading). Mean periods from each infection
(indicated by horizontal lines) were used to assess
statistical significance between genotypes. The
overall mean period was 31.6 hr for full-length
CRY1 and 32.1 hr for D11 CRY1. Steady-state
CRY1 levels for infections 1–4 from each experi-
ment were measured by western blot with Tubulin
shown as loading control.
See also Figures S2 and S3 and Table S1.various stages of the circadian cycle. Deletion of exon 11 results
in the removal of 24 residues from the CRY1 C-terminal tail. In
accordance with previous functional characterizations of the
Cry1 protein regions, we did not observe a difference in the ca-
pacity of CRY1 D11 to inhibit Clock/Bmal1-dependent transcrip-
tion of an E-box-driven luciferase reporter plasmid in heterolo-
gous cell-based assays, which do not require the Cry1 tail
(Chaves et al., 2006; Khan et al., 2012) (Figures S3C and S3D).
Further, although some modifications within the tail region can
affect the half-life of the Cry1 protein under certain conditions
(Gao et al., 2013), we did not observe gross differences in the sta-
bility of CRY1 D11 versus the full-length form in the subject’s pri-
mary fibroblasts (Figure S3E), and luciferase fusion proteins with
the respective CRY1 forms decayed at a similar rate (Figure S3F).
The existence of a nuclear localization signal in the Cry1 tail,
albeit C-terminal to the exon 11 region, prompted us to assess208 Cell 169, 203–215, April 6, 2017the subcellular distribution of the
different CRY1 forms. Unexpectedly,
deletion of exon 11 increased CRY1
abundance in the nuclear fraction of the
proband’s fibroblasts throughout the
circadian cycle (Figures 6A and S4A).
This increased abundance was not
caused by potential additional variations
in the proband’s cells but represents an
intrinsic property of the modified CRY1protein, as enhanced CRY1 D11 nuclear localization was also
observed in DKOMEFs engineered to express both CRY1 forms
(CRY1 fl/D MEFs) (Figures 6B and S4B).
CRY1 D11 Shows Enhanced Interactions with Clock and
Bmal1 Proteins
Preferential nuclear localization of CRY1 D11 led us to assess its
binding to its target transcription factors Clock and Bmal1.
Although both CRY1 forms present in the subject’s fibroblasts
were found to be capable of interaction, the fraction of CRY1 im-
munoprecipitating with ARNTL or Clock was enriched for the
D11 form (Figures 6C and S4C). This is not solely a reflection
of differential subcellular distribution as ARNTL or Clock immu-
noprecipitated from purified nuclear extracts still bound more
D11 than full-length CRY1. Enhanced interaction with the
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Figure 5. Sleep Behavior in CRY1 c.1657+3A>C Carrier Families of Turkish Descent
(A–F) Sleep behavior in families DSPD-4, -6, -14, -1, -9, and -7 assessed through sleep and chronotype questionnaires and personal interview. Genotype is shown
inside symbols. Numbers represent mid-sleep point on free days (MSF) (Roenneberg et al., 2003). See also Table S1 for details.
(G) Legend for colors and symbols used in (A–F).
(H)MSF from subjects in (A–F) aswell as Figure 4A are plotted on a discontinuous clock face from 22:00 to 9:00 for carriers (left, red) and non-carriers (right, black).
No subject data fell within the gap time (9:00 to 22:00) not represented in the plot.of circadian phase (Figures 6D and S4D). Interestingly, although
exon 11 partially overlaps with a region in the Cry1 tail that has
been identified as a binding site for the Bmal1 transactivationdomain acetylated at lysine 538, we still observed preferential
binding of CRY1 D11 to acetylated Bmal1. We also consistently







Figure 6. Exon 11 Deletion Enhances CRY1 Function in the Molecular Circadian Clock
(A) CRY1 expression was assessed in fractionated extracts prepared from the proband’s fibroblasts at the indicated times following synchronization. TUBULIN
and TBP were used as loading controls for cytoplasmic and nuclear extracts, respectively, and to assess fractionation purity.
(B) Same as (A) except proband fibroblasts were replaced with CRY1 fl/DMEFs, and the sampling interval was adjusted to account for the longer circadian period
in this cell type.
(C) Co-immunoprecipitation of CRY1 with ARNTL and CLOCK in unsynchronized whole-cell (left) and nuclear (right) extracts from the proband’s fibroblasts.
(D) Co-immunoprecipitation of CRY1 with Clock, Bmal1, and K538 Acetyl-Bmal1 in nuclear extracts from CRY1 fl/DMEFs at 30 or 45 hr post-synchronization as
well as from unsynchonized CRY1 fl/D and empty vector control DKO MEFs.
(E) Co-immunoprecipitation of Clock, Bmal1, K538 Acetyl-Bmal1, and Per2 with CRY1 from nuclear extracts of CRY1 fl or D11 MEFs at 30 or 45 hr post-syn-
chronization as well as from unsynchronized CRY1 fl or D11 MEFs and the empty vector control.
(legend continued on next page)
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MEFs, which only received empty vector and remained devoid
of cryptochromes, potentially indicating a more complex role
of Bmal1 acetylation than currently suggested. Selective expres-
sion of either the full-length or the CRY1 D11 form in DKO MEFs
allowed us to assess CRY1 binding to its interaction partners in
reciprocal immunoprecipitations of the respective CRY1 form.
Consistent with our other findings, more Clock, acetyl-Bmal1,
and total Bmal1 immunoprecipitated with CRY1 D11 than
with the full-length protein (Figures 6E and S4E). At the same
time, the levels of CRY1-associated Per2 remained similar be-
tween the two CRY1 forms, suggesting the presence of separate
CRY1-containing protein complexeswith differential susceptibil-
ity to exon 11 deletion. Together, these results demonstrate
that, rather than disabling CRY1, deletion of exon 11 enhances
its presence in the nucleus and the binding to its target transcrip-
tion factors, properties that are expected to promote its function
as a transcriptional inhibitor.
CRY1 D11 Strengthens Transcriptional Inhibition
To directly test whether CRY1 D11 acts as a more potent tran-
scriptional inhibitor during the intact clock cycle, we compared
the expression of selected target genes in our engineered cell
lines expressing either full length or CRY1 D11. As expected,
cyclic CRY1 expression restored the circadian oscillation of
pre-Bmal1, pre-Per2, pre-Per1, and pre-Dbp mRNAs with a
long-period rhythm, although the sampling interval impeded an
accurate determination of period length, as previously achieved
by the high-resolution luciferase assay (Figure 6F). Compared to
CRY1 full-length cells, the levels of pre-Per2, pre-Per1, and
pre-Dbp mRNAs were reduced in CRY1 D11 cells, demon-
strating stronger repression of Clock/Bmal1-mediated tran-
scription by CRY1 D11 consistent with its other properties. In
contrast, expression of pre-Bmal1, which is controlled by a
different set of regulatory elements (Preitner et al., 2002; Ueda
et al., 2002), remained unaffected by the CRY1 modification,
as did the levels of a non-circadian control gene.
Given enhanced association with the target transcription fac-
tors as well as reduced expression of the relevant transcripts,
we wondered whether exon 11 deletion affected CRY1 occu-
pancy at its target gene promoters. In the circadian transcrip-
tional feedback loop, repression can occur by blocking of the
DNA-bound transcription factors or by their displacement and
sequestration away from DNA (Menet et al., 2010). Cry1-depen-
dent inhibition of gene expression has been shown to involve
both of these modes (Ye et al., 2014). Using our cell lines
engineered to selectively express full length or CRY1 D11, we
measured the binding of CRY1, Bmal1, and Clock to target
regions in the Per2 and Dbp promoters by chromatin immuno-
precipitation (Figures 7A–B). At the time of high Bmal1/low
Per2 expression, reduced promoter association of CRY1,
Bmal1, and Clock was observed in cells expressing CRY1 D11
compared to the full-length form, while the association of the
control histone 3 trimethylated at lysine 4 (H3K4me3) remained(F) Levels of CRY1, pre-Bmal1, pre-Per2, pre-Per1, pre-Dbp, and pre-Lrwd1 wer
D11 (red) MEFs. Graphs show mean expression levels from five independent e
significant differences in gene expression between genotypes are indicated. n.s
See also Figure S4.unaltered. As expected, in control reactions measuring a non-
circadian promoter, only H3K4me3 binding was observed while
the amounts of CRY1, Bmal1, and Clock were at or near the
background levels of the assay (Figure 7C). These results
demonstrate that CRY1 exon 11 deletion specifically reduces
the presence of clock gene proteins at target gene pro-
moters, consistent with Cry1-mediated transcriptional regulation
through displacement of Clock and Bmal1.
DISCUSSION
As themajor transcriptional inhibitor in the negative feedback loop
that constitutes the core molecular clock, Cry1 represents a crit-
ical regulator of circadian period length. In general, there is a pos-
itive correlation between the amount of Cry1 and period length,
although exceptions to this rule can occur upon manipulation of
selected protein regions (Busino et al., 2007; Godinho et al.,
2007; Hirota et al., 2012; Ode et al., 2016; Oshima et al., 2015;
Siepka et al., 2007; van der Horst et al., 1999; Vitaterna et al.,
1999;Zhangetal., 2009).Moreover,period lengthhasbeenshown
to correlate with the affinity of Cry1 to Bmal1 (Xu et al., 2015).
Our results show that theCRY1DSPD allele represents a gain-
of-functionmutationwith deletion of exon11 leading to increased
CRY1 nuclear localization, enhanced interaction with the tran-
scription factors Clock and Bmal1, their displacement from chro-
matin, and heightened inhibition of their target genes (Figure S5).
Expression of this more potent CRY1 form (CRY1 D11) is associ-
ated with a lengthened period of molecular circadian rhythms in
cells. A human carrier of CRY1 D11 studied in temporal isolation
displayed corresponding, long-period behavioral and body-tem-
perature rhythms with diminished amplitudes. These phenotypic
changes are consistent with the established positive correlation
of period length with CRY1 availability and affinity to its target
transcription factors, thus providing a mechanistic explanation
for the development of DSPD in carriers of the CRY1 D11 allele.
The stronger inhibitory function of the CRY1D11 variant is only
observed in the context of an intact clock cycle, raising inter-
esting questions regarding the mechanism by which the CRY1
protein tail influences Clock/Bmal1 transcriptional activity. While
currently available structural characterizations of themammalian
cryptochrome proteins have been insightful regarding their bind-
ing to Per2 and Fbxl3, the interaction with their target transcrip-
tion factors has yet to be visualized, and none of the structures
includes the Cry1 tail region (Merbitz-Zahradnik and Wolf,
2015). It is conceivable that the tail could affect transcription
factor/repressor interaction through regulated binding to the
CRY1 photolyase homology region or Clock/Bmal1, causing
conformational changes to the complex. Such an event could
be temporally controlled through recruitment or loss of additional
complex components, through inducible post-translational
modification of any of the proteins, or through changes to the
CRY1 protein such as its redox state or the presence of cofac-
tors, including flavin adenine dinucleotide or zinc ions. Whilee assessed by real-time quantitative RT-PCR in synchronized CRY1 fl (blue) or
xperiments, with the shaded area indicating the standard error. Statistically
., not significant.




Figure 7. CRY1 D11 Affects the Occupancy
of CRY1, Bmal1, and Clock at Target Gene
Promoters
(A–C) CRY1, Bmal1, Clock, and H3K4me3 were
immunoprecipitated from CRY1 fl (blue) or D11
(red) MEFs at 30 or 45 hr post-synchronization
following chromatin crosslinking. The amount of
Per2- (A), Dbp- (B), and Lrwd1-promoter DNA (C)
in the immunoprecipitates was assessed by real-
time quantitative PCR. The background signal
(dashed line) corresponds to the respective
real-time quantitative PCR values of a control re-
action using a CRY1 chromatin-immunoprecipi-
tate from Cry-deficient cells as template. Data in
each experiment were normalized to the amount in
the CRY1 fl sample, which was set to 1. Error bars
represent the standard error from three indepen-
dent experiments.dispensable for basic repression, the CRY1 tail could thus exert
the capacity to modulate transcriptional inhibition at defined
stages of the circadian cycle.
In our analyses of cellular circadian rhythms, the CRY1 D11
allele consistently lengthened the period of molecular oscilla-
tions by approximately half an hour. Earlier work has demon-
strated a strong relationship between circadian period, entrained
phase, and sleep timing in humans, such that moderate changes
in period are associated with much larger shifts in the relative
phases of bedtime and the evening increase in serum melatonin
(Gronfier et al., 2007; Wright et al., 2005). Accordingly, a half-
hour change in the period of the human circadian clock is ex-
pected to change the relationship of sleep timing and evening212 Cell 169, 203–215, April 6, 2017melatonin onset (DLMO) by 2–2.5 hr.
These predictions agree well with the
behavioral and physiological findings we
have presented.
Databases of human genetic variation
report a frequency between 0.1% and
0.6% for the CRY1 c.1657+3A>C allele,
such that up to 1 in 75members of certain
populations could carry the dominant
CRY1 variant. Our analyses of the original
proband family as well as a large number
of subjects from unrelated families of
completely different ethnicity show that
both homo- and heterozygous CRY1
c.1657+3A>C carrier status is strongly
associated with late sleep times and
sleep fragmentation. Possibly, the latter
behaviormay be amanifestation of carrier
allele status under environmental condi-
tions that do not accommodate late sleep
times, as can often be the case due to cul-
tural, social, or professional obligations.
Alternatively, inter-individual differences
in genetic background or exposure to
environmental entrainment signals may
affect the nature and penetrance of sleepdisturbances inCRY1D11 allele carriers, and similar phenomena
have been observed in both human and animal studies of circa-
dian rhythmicity (Azzi et al., 2014; Pittendrigh and Daan, 1976;
Shimomura et al., 2013; Toh et al., 2001). The CRY1 D11 variant
may thus lead to a broader range of sleep-disorder phenotypes
with delay being the most common manifestation.
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Rockefeller University Women & Science Postdoctoral Fellowship program
(A.P.), and a NARSAD Young Investigator Grant #21131 from the Brain &
Behavior Research Foundation (A.P.). P.J.M is currently employed by Eisai Inc.
Received: January 14, 2017
Revised: February 18, 2017
Accepted: March 20, 2017
Published: April 6, 2017
REFERENCES
American Academy of Sleep Medicine (2005). International Classification of
Sleep Disorders: Diagnostic and Coding Manual, Second Edition (Westches-
ter, Illinois: American Academy of Sleep Medicine).
Anand, S.N., Maywood, E.S., Chesham, J.E., Joynson, G., Banks, G.T.,
Hastings, M.H., and Nolan, P.M. (2013). Distinct and separable roles for
endogenous CRY1 and CRY2 within the circadian molecular clockwork
of the suprachiasmatic nucleus, as revealed by the Fbxl3(Afh) mutation.
J. Neurosci. 33, 7145–7153.
Aoki, H., Ozeki, Y., and Yamada, N. (2001). Hypersensitivity of melatonin sup-
pression in response to light in patients with delayed sleep phase syndrome.
Chronobiol. Int. 18, 263–271.
Archer, S.N., Robilliard, D.L., Skene, D.J., Smits, M., Williams, A., Arendt, J.,
and von Schantz, M. (2003). A length polymorphism in the circadian clock
gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal
preference. Sleep 26, 413–415.
Azzi, A., Dallmann, R., Casserly, A., Rehrauer, H., Patrignani, A., Maier, B.,
Kramer, A., and Brown, S.A. (2014). Circadian behavior is light-reprogrammed
by plastic DNA methylation. Nat. Neurosci. 17, 377–382.
Barclay, N.L., Eley, T.C., Buysse, D.J., Archer, S.N., and Gregory, A.M. (2010).
Diurnal preference and sleep quality: same genes? A study of young adult
twins. Chronobiol. Int. 27, 278–296.
Benloucif, S., Burgess, H.J., Klerman, E.B., Lewy, A.J., Middleton, B., Murphy,
P.J., Parry, B.L., and Revell, V.L. (2008). Measuring melatonin in humans.
J. Clin. Sleep Med. 4, 66–69.
Brown, S.A., Fleury-Olela, F., Nagoshi, E., Hauser, C., Juge, C., Meier, C.A.,
Chicheportiche, R., Dayer, J.M., Albrecht, U., and Schibler, U. (2005). The
period length of fibroblast circadian gene expression varies widely among
human individuals. PLoS Biol. 3, e338.
Busino, L., Bassermann, F., Maiolica, A., Lee, C., Nolan, P.M., Godinho, S.I.,
Draetta, G.F., and Pagano, M. (2007). SCFFbxl3 controls the oscillation of
the circadian clock by directing the degradation of cryptochrome proteins.
Science 316, 900–904.
Campbell, S.S., andMurphy, P.J. (2007). Delayed sleep phase disorder in tem-
poral isolation. Sleep 30, 1225–1228.
Chang, A.M., Reid, K.J., Gourineni, R., and Zee, P.C. (2009). Sleep timing
and circadian phase in delayed sleep phase syndrome. J. Biol. Rhythms 24,
313–321.
Chaves, I., Pokorny, R., Byrdin, M., Hoang, N., Ritz, T., Brettel, K., Essen, L.O.,
van der Horst, G.T., Batschauer, A., and Ahmad, M. (2011). The crypto-
chromes: blue light photoreceptors in plants and animals. Annu. Rev. Plant
Biol. 62, 335–364.
Chaves, I., Yagita, K., Barnhoorn, S., Okamura, H., van der Horst, G.T., and
Tamanini, F. (2006). Functional evolution of the photolyase/cryptochrome
protein family: importance of the C terminus of mammalian CRY1 for circadian
core oscillator performance. Mol. Cell. Biol. 26, 1743–1753.
Chiou, Y.Y., Yang, Y., Rashid, N., Ye, R., Selby, C.P., and Sancar, A. (2016).
Mammalian Period represses and de-represses transcription by displacingCell 169, 203–215, April 6, 2017 213
CLOCK-BMAL1 from promoters in a Cryptochrome-dependent manner. Proc.
Natl. Acad. Sci. USA 113, E6072–E6079.
Ciarleglio, C.M., Ryckman, K.K., Servick, S.V., Hida, A., Robbins, S., Wells, N.,
Hicks, J., Larson, S.A., Wiedermann, J.P., Carver, K., et al. (2008). Genetic dif-
ferences in human circadian clock genes among worldwide populations.
J. Biol. Rhythms 23, 330–340.
Cingolani, P., Platts, A., Wang, Le, L., Coon, M., Nguyen, T., Wang, L., Land,
S.J., Lu, X., and Ruden, D.M. (2012). A program for annotating and predicting
the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of
Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80–92.
Crane, B.R., and Young, M.W. (2014). Interactive features of proteins
composing eukaryotic circadian clocks. Annu. Rev. Biochem. 83, 191–219.
Czarna, A., Breitkreuz, H., Mahrenholz, C.C., Arens, J., Strauss, H.M., and
Wolf, E. (2011). Quantitative analyses of cryptochrome-mBMAL1 interactions:
mechanistic insights into the transcriptional regulation of the mammalian
circadian clock. J. Biol. Chem. 286, 22414–22425.
Czeisler, C.A., Duffy, J.F., Shanahan, T.L., Brown, E.N., Mitchell, J.F., Rimmer,
D.W., Ronda, J.M., Silva, E.J., Allan, J.S., Emens, J.S., et al. (1999). Stability,
precision, and near-24-hour period of the human circadian pacemaker. Sci-
ence 284, 2177–2181.
Danecek, P., Auton, A., Abecasis, G., Albers, C.A., Banks, E., DePristo, M.A.,
Handsaker, R.E., Lunter, G., Marth, G.T., Sherry, S.T., et al.; 1000 Genomes
Project Analysis Group (2011). The variant call format and VCFtools. Bioinfor-
matics 27, 2156–2158.
DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire, J.R., Hartl, C.,
Philippakis, A.A., del Angel, G., Rivas, M.A., Hanna, M., et al. (2011). A
framework for variation discovery and genotyping using next-generation
DNA sequencing data. Nat. Genet. 43, 491–498.
Duffy, J.F., Rimmer, D.W., and Czeisler, C.A. (2001). Association of intrinsic
circadian period with morningness-eveningness, usual wake time, and circa-
dian phase. Behav. Neurosci. 115, 895–899.
Duong, H.A., Robles, M.S., Knutti, D., and Weitz, C.J. (2011). A molecular
mechanism for circadian clock negative feedback. Science 332, 1436–1439.
Duong, H.A., and Weitz, C.J. (2014). Temporal orchestration of repressive
chromatin modifiers by circadian clock Period complexes. Nat. Struct. Mol.
Biol. 21, 126–132.
Ebisawa, T., Uchiyama, M., Kajimura, N., Mishima, K., Kamei, Y., Katoh, M.,
Watanabe, T., Sekimoto, M., Shibui, K., Kim, K., et al. (2001). Association of
structural polymorphisms in the human period3 genewith delayed sleep phase
syndrome. EMBO Rep. 2, 342–346.
Gao, P., Yoo, S.H., Lee, K.J., Rosensweig, C., Takahashi, J.S., Chen, B.P., and
Green, C.B. (2013). Phosphorylation of the cryptochrome 1 C-terminal tail reg-
ulates circadian period length. J. Biol. Chem. 288, 35277–35286.
Godinho, S.I., Maywood, E.S., Shaw, L., Tucci, V., Barnard, A.R., Busino, L.,
Pagano, M., Kendall, R., Quwailid, M.M., Romero, M.R., et al. (2007). The
after-hoursmutant reveals a role for Fbxl3 in determiningmammalian circadian
period. Science 316, 897–900.
Griffin, E.A., Jr., Staknis, D., and Weitz, C.J. (1999). Light-independent role of
CRY1 and CRY2 in the mammalian circadian clock. Science 286, 768–771.
Gronfier, C., Wright, K.P., Jr., Kronauer, R.E., and Czeisler, C.A. (2007).
Entrainment of the human circadian pacemaker to longer-than-24-h days.
Proc. Natl. Acad. Sci. USA 104, 9081–9086.
Hawkins, G.A., Meyers, D.A., Bleecker, E.R., and Pack, A.I. (2008). Identif-
ication of coding polymorphisms in human circadian rhythm genes PER1,
PER2, PER3, CLOCK, ARNTL, CRY1, CRY2 and TIMELESS in a multi-ethnic
screening panel. DNA Seq. 19, 44–49.
Hida, A., Kitamura, S., Katayose, Y., Kato, M., Ono, H., Kadotani, H.,
Uchiyama, M., Ebisawa, T., Inoue, Y., Kamei, Y., et al. (2014). Screening of
clock gene polymorphisms demonstrates association of a PER3 polymor-
phism with morningness-eveningness preference and circadian rhythm sleep
disorder. Sci. Rep. 4, 6309.214 Cell 169, 203–215, April 6, 2017Hirano, A., Shi, G., Jones, C.R., Lipzen, A., Pennacchio, L.A., Xu, Y., Hallows,
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit polyclonal anti-Cry1 Bethyl Laboratories Cat# A302-614A; RRID: AB_10555376
Rabbit polyclonal anti-Bmal1 Bethyl Laboratories Cat# A302-616A; RRID: AB_10555918
Rabbit polyclonal anti-Clock Bethyl Laboratories Cat# A302-618A; RRID: AB_10555233
Rabbit polyclonal anti-NFX1 Bethyl Laboratories Cat# A302-914A; RRID: AB_10663488
Rabbit polyclonal anti-Per2 Alpha Diagnostics Cat# PER21-A
Rabbit polyclonal anti-acetyl BMAL1 (Lys538) Millipore Cat# AB15396; RRID: AB_11212017
Rabbit monoclonal anti-Trimethyl-Histone H3 (Lys4) Millipore Cat# 17-614; RRID: AB_11212770
Mouse monoclonal anti-a-Tubulin clone DM1A Sigma Cat# T6199; RRID: AB_477583
Mouse monoclonal anti-TATA binding protein TBP Abcam Cat# 51841; RRID: AB_945758
Chemicals, Peptides, and Recombinant Proteins
Forskolin Sigma-Aldrich Cat# F3917
D-Luciferin Firefly, Potassium salt Biosynth Cat# L-8220
Critical Commercial Assays
Bühlmann Direct Saliva Melatonin Radio Immunoassay kit ALPCO Diagnostics Cat# 01-RK-DSM2
Oragene DNA Self-Collection kit DNA Genotek Cat# OG-500
Dual-Luciferase Reporter Assay System Promega Cat# E1910
Agilent SureSelect Human All Exon V4 capture kit Agilent Technologies Design ID: S03723314
Deposited Data
GRCh37 1000 Genomes http://www.internationalgenome.org/
Human subject details This study Table S1
Experimental Models: Cell Lines
Primary human dermal fibroblasts This study N/A
Cry-deficient mouse embryonic fibroblasts Ukai-Tadenuma et al., 2011 N/A
HEK293T/17 ATCC Cat# CRL-11268
Recombinant DNA
pLenti6-Bmal1-dLuc Liu et al., 2008 N/A
psPax2 Addgene Cat# 12260
pMD2G Addgene Cat# 12259
pLV6puro-hCry1fl This study N/A
pLV6puro-hCry1D This study N/A
pLV6puro-promoter This study N/A
pcDNA3HA-hCry1fl This study N/A
pcDNA3HA-hCry1fl This study N/A
pcDNA3F-hBmal1 This study N/A
pcDNA3F-hClock This study N/A
pGL3-AVP Kume et al., 1999 N/A
pGL3-Per2dLuc Ueda et al., 2002 N/A
pcDNA3F-hCry1fl-luc This study N/A
pcDNA3F-hCry1D-luc This study N/A
Sequence-Based Reagents
Primers for RT-PCR, see Table S3
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Primers for ChIP, see Table S3
Primers for genotyping, see Table S3
Software and Algorithms
PSG TWin (version 4.1.) Grass Technologies,
Natus Neurology
http://www.natus.com/
ClockLab (version 2.72) Actimetrics http://actimetrics.com/downloads/clocklab/
Lumicycle (version 2.54) Actimetrics http://actimetrics.com/downloads/lumicycle/
Prism (version 5.0c) GraphPad Software https://www.graphpad.com/scientific-software/prism/
ImageJ (version 1.49v) NIH https://imagej.nih.gov/ij
Burrows-Wheeler Aligner (BWA version 0.7.8) Li and Durbin, 2009 http://bio-bwa.sourceforge.net/
Picard (version 1.83) Broad Institute https://broadinstitute.github.io/picard/
GATK (Genome Analysis Toolkit version 3.2-2) DePristo et al., 2011 http://gatkforums.broadinstitute.org/gatk
SnpEff (version 3.4b) Cingolani et al., 2012 http://snpeff.sourceforge.net/
VCFtools (version 0.1.11) Danecek et al., 2011 https://vcftools.github.io/index.html
Ensembl Variant Effect Predictor McLaren et al., 2016 http://grch37.ensembl.org/Homo_sapiens/Tools/VEP
Other
Aura PSG Lite portable polysomnography system Grass Technologies,
Natus Neurology
http://www.natus.com/
VitalSense telemetric core body temperature
monitoring system
Philips Respironics http://www.actigraphy.com/solutions/vitalsense/
Actiwatch activity monitoring system Philips Respironics http://www.actigraphy.com/solutions/actigraphy.htmlCONTACT FOR REAGENT AND RESOURCE SHARING
For reagents generated in this study or any other questions about the reagents please contact the Lead Contact Michael W. Young
(young@rockefeller.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Studies
Human subject research was approved by Institutional Review Boards at Weill Cornell Medical College (WCMC protocol
0609008750) and The Rockefeller University (RU protocol APA-0777) and the ethics committee at Bilkent University. Subjects’
written informed consent was obtained prior to any study procedures. Subject details can be found in Table S1.
Subject Screening for Human In-Laboratory Study
Sleep behavior was assessed through sleep interview, sleep and chronotype questionnaires and at-home actigraphy (Actiwatch-L,
Philips Respironics) combined with a sleep log prior to arrival at the laboratory. Eligibility required habitual bedtimes between 22:30 –
00:30 with habitual waketimes between 06:00 – 09:00 for controls and habitual bedtimes later than 02:00 with habitual waketimes
later than 10:00 for DSPD subjects. Subjects were confirmed to be in good physical and mental health at the time of study
participation based on physical exam, urine toxicology screen, structured diagnostic interview (SCID-R) and Hamilton Depression
Rating Scale.
Data Collection for Human In-Laboratory Study
Subjects resided in a research studio apartment, which was located within the WCMC Laboratory of Human Chronobiology and
shielded from all cues to time-of-day. Closed-circuit TV allowed for observation of subjects and communication was possible through
an intercom system. Laboratory personnel also intermittently entered the research apartment for in-person interaction as necessary.
Illumination was limited to a maximum of 100 lux with average values between 30 and 50 lux, except during sample collection
for salivary DLMO when maximum illumination at the eye level when subjects were seated was set to 16 lux. Continuous electroen-
cephalogram (EEG), electrooculogram (EOG) and electromyogram (EMG) were recorded using a portable polysomnography (PSG)
system (Aura PSG Lite, Grass Technologies, Natus Neurology, West Warwick, RI) and a PSG electrode montage consisting of 6
referential EEG derivations referenced to linked mastoids. Core body temperature was recorded in 1 min intervals using ingestible
telemetric temperature sensors with an external wireless data receiver (VitalSense, Philips Respironics). Saliva samples for DLMOCell 169, 203–215.e1–e8, April 6, 2017 e2
determination were collected in 30 min intervals on the evening leading up to the second entrainment night starting at 18:00 until
bedtime. Subjects were instructed to sit quietly and refrain from eating or drinking prior to each sample collection. Samples were
collected using Salivette tubes (ALPCO Diagnostics, Windham NH) and stored frozen until analysis by the Yerkes Endocrine Assay
Laboratory of Emory University using the Bühlmann Direct Saliva Melatonin Radio Immunoassay kit (ALPCO Diagnostics, Windham
NH). A fixed threshold of 3 pg/ml was used for DLMO estimation (Benloucif et al., 2008).
Proband Family Study
Sleep behavior was assessed by sleep and chronotype questionnaires and sleep interview (in-person or via phone). Select subjects
also compliedwith a request tomaintain a sleep log for 14 days (see Figure S2). Genomic DNAwas isolated from saliva (Oragene DNA
Self-Collection kit, DNA genotek) and, additionally for select subjects, whole blood (BD Vacutainer K2 EDTA) using the Gentra Pure-
gene Blood Kit (QIAGEN).
Reverse Phenotyping of additional CRY1 c.1657+3A>C Carrier Families
Carriers of the CRY1 c.1657+3A>C allele were identified from an in-house exome database of families with metabolic and neuro-
degenerative phenotypes at Bilkent University and from databases maintained by the University and Scientific and Technological
Research Council of Turkey, Advanced Genomics and Bioinformatics Research Center (TÜB_ITAK-IGBAM, http://www.igbam.
bilgem.tubitak.gov.tr/en/index.html). Neither of these databases is publicly accessible. Requests for materials, data, and further
information should be addressed to Tayfun Ozcelik (tozcelik@bilkent.edu.tr, see also Data And Software Availability). Ethics
and consent procedures for subjects in these databases allow for re-contact. Upon outreach from Bilkent University investigators,
subjects in seven families (DSPD-1, 2, 4, 6, 7, 9 and 14) consented to characterization of their sleep behavior and dona-
tion of a DNA sample for genotyping. Habitual sleep times were determined from questionnaires and factors that could potentially
confound sleep characterization were assessed through interview (in-person or via phone). The latter included any relevant comor-
bidities and medications as well as environmental factors such as current or former shift work, religious observances (5 am prayer)
and family circumstances (influence of spouse on bed and wake times, number of young children, pregnancy). One family DSPD-2
was excluded from further analysis after data collection because of complete co-segregation of aberrant sleep in carriers with
morbid obesity and obstructive sleep apnea. For the remaining families, subjects were classified into the following categories:
affected late, affected fragmented, probably affected, probably not affected, not affected or uninterpretable. Factors that contrib-
uted to the classification of each subject are listed in Table S1. For the statistical analysis of the association of sleep behavior with
CRY1 allele status, the first three categories were combined as ‘affected’ and the third and fourth category were combined as
‘unaffected’. P value from Fisher’s exact test, odds ratio and 95% confidence interval were calculated in Prism 5 (GraphPad
Software). Note: The term carrier is used in this work in reference to individuals who carry one or two copies of the dominant
CRY1 c.1657+3A>C allele, analogous to common practice in clinical settings for disease-linked dominant genetic variants. This
nomenclature should not to be confused with the classical genetic definition of a carrier as an individual carrying a recessive allele
who is unaffected by the trait.
Derivation of Human Dermal Fibroblast Cell Lines
A 4mm full thickness skin punch biopsy was taken from a subject’s thigh under local anesthesia and immediately transferred to a vial
containing sterile storage medium (DMEM with 50% fetal bovine serum (FBS)). Tissue processing for establishment of dermal fibro-
blast cell lines was performed within the next several hours using the following procedure modified from Brown et al. (Brown et al.,
2005). Briefly, samples were digested overnight in primary culture medium (DMEM containing 20% FBS, antibiotics (100 U/ml peni-
cillin and 100 mg/ml streptomycin (GIBCO, Life Technologies)), 2.5 mg/ml Amphotericin B (Sigma)) supplemented with 100 mg/ml
Collagenase Type I (GIBCO, Life Technologies) and 100 mg/ml Dispase (GIBCO, Life Technologies). Cells were cultured in primary
culture medium until the first passage when the FBS concentration was reduced to 10% and Amphotericin B was omitted from
the culture medium.
Cell Lines and Tissue Culture
Primary dermal fibroblast cell lines were derived from a subject’s skin punch biopsy as described above. 293T cells were obtained
from ATCC. Cry1/2 double knockout mouse embryonic fibroblasts (DKO MEFs) have been described (Ukai-Tadenuma et al., 2011).
Cells were maintained in standard culture medium DMEM (Invitrogen, Life Technologies) with antibiotics (100 U/ml penicillin and
100 mg/ml streptomycin (GIBCO, Life Technologies)) and fetal bovine serum (10% FBS for dermal fibroblasts and 293T cells, 2%
FBS for DKOMEFs). For clock synchronization, cells were treated with 20 mM forskolin (Sigma) in culturemedium for 1.5 hr. Lentivirus
was prepared by transient transfection of 293T cells with second generation lentiviral vectors using standard calcium phosphate
transfection methods. Filtered, unconcentrated supernatant with 8 mg/ml polybrene (Millipore) was used for transduction. Selection
antibiotic (10 mg/ml blasticidin or 2.5 mg/ml puromycin, both Invivogen) was added to cell culture medium three days post-
transduction.e3 Cell 169, 203–215.e1–e8, April 6, 2017
METHOD DETAILS
Candidate Gene Sequencing
cDNAs for the below listed clock genes were cloned from total RNA isolated from the proband TAU11 dermal fibroblast cell line and
sequenced by Sanger sequencing. In addition to the CRY1 c.1657+3A>C variant, the following coding variations were identified
(variants are listed with dbSNP identifier and alternate allele frequency):PER1 (GenBank: NM_002616.2, NP_002607.2)
c.2884G>C (p.Ala962Pro) rs2585405 AF 1-0.2282
c.2992G>A (p.Ala998Thr) rs112474322 AF 0.0154
PER2 (GenBank: NM_022817.2, NP_073728.1)
c.1201C>T (p.Arg401Cys) rs77146655 AF 0.0106
PER3 (GenBank: NM_016831.2, 058515.1)
c.1916T>G (p.Val639Gly) rs10462020 AF 0.1206
c.2480T>C (p.Leu827Pro) rs228696 AF 1-0.0248
c.3083T>C (p.Met1028Thr) rs2640909 AF 0.1853
c.3446A>C (p.His1149Arg) rs10462021 AF 0.1210
CRY1: no additional coding change
CRY2, ARNTL, CLOCK, CSNK1D: no coding changeThe presence of additional polymorphisms is not unexpected given the large degree of variation commonly found in some human
clock genes (Ciarleglio et al., 2008; Hawkins et al., 2008). ThePER1 polymorphismswere not considered likely DPSD alleles based on
high allele frequency and their presence in control subjects of normal chronotype. Regarding the PER2 variant, the arginine to
cysteine amino acid change appears to constitute a reversion to the ancestral allele based on the fact that this position encodes
a cysteine in both human PER1 and PER3 as well as in many vertebrate members of the Per2 family with the exception of placental
mammals. Although a functional effect of this amino acid change is thus unlikely, we assessed its segregation with aberrant sleep in
the proband kindred. Based on absence of the PER2 allele in the proband’s affected mother TAUX01 and nieces TAUX08 and
TAUX10, the variant was disregarded as a potential DSPD allele. Although several coding variations in PER3 have been associated
with late chronotype and DPSD behavior (Archer et al., 2003; Ebisawa et al., 2001; Hida et al., 2014), subsequent studies have often
struggled to reproduce these findings, possibly due to limited sample and effect sizes or population-specific correlations in the orig-
inal studies (Kripke et al., 2014; Osland et al., 2011; Pereira et al., 2005). Among the proposed PER3 polymorphisms, the Val639Gly
allele was detected in the TAU11 proband as well as several of our other subjects (both DSPD and normal chronotype controls).
Although the fact that this allele is not uncommon in normal controls argues against a causal role of the variant in delayed sleep
behavior, we assessed its segregation with aberrant sleep patterns in the proband kindred. We found the alternate allele to be
very common in both heterozygous and homozygous forms throughout the family albeit with poor behavioral correlation (e.g., unaf-
fected cousin TAUX04 is homozygous carrier, whereas affected niece TAUX10 lacks alternate Gly allele). Although it remains possible
that the presence of this allele may influence chronotype preference in conjunction with additional genetic or environmental factors
yet to be characterized, these results do not support a causal role of this variant in sleep behavior in the proband kindred.
Whole Exome Sequencing
Genomic DNA was isolated from the proband fibroblast cell line or whole blood samples from subjects TAUX01-04 using the Gentra
Puregene Blood Kit (QIAGEN). Whole exome sequencing (WES) was performed by the New York Genome Center as follows: Exome
capture was performed using Agilent SureSelect Human All Exon V4 capture kit. 100 bp paired-end sequencing was done on Illumina
HiSeq 2500. Sequences were aligned to human genome build GRCh37 using BWA (Burrows-Wheeler Aligner) (Li and Durbin, 2009).
Duplicate reads were marked using Picard (http://picard.sourceforge.net). GATK (Genome Analysis Toolkit) (DePristo et al., 2011)
was used for base quality score recalibration (BQSR) and local realignment around indels to refine alignment artifacts around putative
insertions or deletions. Variant discovery was performed in two steps - variant calling with GATK HaplotypeCaller followed by joint
genotyping using GATK GenotypeGVCFs. The resulting variant call set was refined using Variant Quality Score Recalibration (VQSR)
as implemented in GATK VariantRecalibrator. The VQSR scores were used to define low quality variants for downstream processing.
SnpEff (Cingolani etal., 2012) andVCFtools (Daneceketal., 2011)wereused toaddvarianteffectpredictionsand functional annotations.
WES of the proband TAU11 confirmed all previously identified variants, but did not identify any additional coding variations in the
above studied clock genes or additional candidate genes CSNK1E, ARNTL2, FBXL3, FBXL21, BHLHE40, BHLHE41, NR1D1 and
RORA. A single coding variation was detected in TIMELESS c.2492G>A (p.Arg831Gln), which was not considered further based
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WES of four affected family members (TAU11, TAUX01, TAUX02, TAUX03) and one unaffected family member (TAUX4) of the pro-
band’s family was carried out in order to identify all potentially functional genetic variants co-segregating with the sleep phenotype.
Variants were annotated, then filtered as follows: (1) to include only variants with minor allele frequencies < 0.01 in the 1000 Genomes
combined population using Ensembl Variant Effect Predictor (McLaren et al., 2016) or in the ExAC total population (Lek et al., 2016);
(2) to include only variants at a site with gerp score > 2.0 or a nonsynonymous change with PolyPhen score > 0.40 (PolyPhen-2
v2.2.2r398); and (3) to include only variants shared by all affected family members and not present in the unaffected family member.
Among the remaining variants (Table S2), the CRY1 c.1657+3A>C allele was the only variant affecting a gene with a known or impli-
cated role in the regulation of sleep or circadian rhythmicity.
Of the additional clock gene coding variations found in the proband TAU11 (see above), none segregated with sleep behavior in the
additional exome-sequenced subjects:TAUX01 (affected) TAUX02 (affected) TAUX03 (affected) TAUX04 (not affected)
rs2585405 present present present present
rs112474322 not present not present present not present
rs77146655 not present present present not present
rs10462020 present present present present
rs228696 present present present present
rs2640909 present present present present
rs10462021 present present present presentCRY1 c.1657+3A>C Genotyping
For CRY1 genotyping, a 623 base pair fragment of the genomic locus containing exon 11 was PCR amplified using oligos hCry1i10F
and hCry1i12R (Table S3). The product was either Sanger-sequenced or tested for a restriction fragment length polymorphism for
Hpy188I (+ allele: no cut, variant c.1657+3A>C: 276 bp + 347 bp).
Cloning of CRY1 Constructs
Human CRY1 full-length (fl) and D11 cDNAs were PCR amplified from a first-strand cDNA library from the proband fibroblast cell line
and blunt-cloned into the EcoRV-site of pBluescript. Sequences were confirmed by Sanger-sequencing. Aside from the 72 base
pairs missing in D11, sequences were identical to Refseq human CRY1 (GenBank: NM_004075.4) with the exception of a common
silent variant c.636T>C (p.Gly212=, rs8192440, AF 1-0.2103) present in bothCRY1 forms. ORFswere subcloned in frame into amodi-
fied pcDNA3.1 vector (Invitrogen, Life Technologies) containing an N-terminal triple-HA tag using EcoRV/NotI restriction sites. For
lentiviral expression, CRY1 fl and D11 were PCR-amplified and first subcloned into pMU2-P(Cry1)-(Cry1 intron336)-Cry1 (Ukai-Ta-
denuma et al., 2011) fromwhich themCry1 cDNA had been excised using XbaI/NotI restriction sites, yielding pMU2-hCry1fl andD11.
The mCry1 expression cassette of pMU2-P(Cry1)-(Cry1 intron336)-Cry1, including promoter, intronic sequence and mCry1 cDNA
was transferred into a modified pLenti6 vector (Invitrogen, Life Technologies), in which the blasticidin resistence cassette had
been replaced with puromycin using SalI/MluI restriction sites, yielding pLV6puro-mCry1. To generate pLV6puro-hCry1fl and
D11,mCry1 in pLV6puro-mCry1 was replaced with CRY1 cDNAs amplified from pMU2-hCry1 constructs using XbaI/MluI restriction
sites. To generate an ‘empty vector’ control containing only theCry1 regulatory elements without cDNA, the XbaI/MluI-digested vec-
tor was blunted with T4 DNA polymerase and religated.
Real-Time Circadian Reporter Assay
Cry DKO MEFs were transduced with a lentiviral Bmal-luc reporter (Liu et al., 2008) and with lentiviral CRY1 fl or D11 (pLV6puro-
hCry1fl and D11) and selected for transgene expression using appropriate selection antibiotics. Cells were plated and grown to
confluence in 35 mm dishes (BD Falcon) and synchronized with 20 mg/ml forskolin (Sigma) for 1.5 hr. Medium was replaced with
counting medium (phenol red-, L-glutamine- and bicarbonate-free DMEM (Cellgro), 100 U/ml penicillin and 100 mg/ml streptomycin,
2% FBS, 350 mg/l sodium bicarbonate (GIBCO), 10 mM HEPES pH 7.2 (GIBCO), 2 mM L-glutamine (GIBCO), 0.5 mM firefly
D-luciferin potassium salt (Biosynth)) and dishes were sealed with high vacuum grease (Dow Corning). Bioluminescence was re-
corded for approximately seven days in a Lumicycle luminometer (Actimetrics) with counts collected in 10 min intervals for each
dish. The first 20 hr of recorded data were excluded from analysis. Period analysis was performed by fitting a damped sine curve
to time series data detrended by subtracting a running average using Lumicycle analysis software (Actimetrics). Goodness-of-fit
values for curve fitting were routinely above 90%. Statistical significance between genotypes was assessed using an unpaired t test.
Preparation of Protein Extracts, Immunoprecipitation, and Western Blot
For subcellular fractionation, cells were first lysed in buffer 1 containing 320 mM sucrose, 10 mM Tris-HCl pH 8.0, 3 mMCaCl2, 2 mM
Mg Acetate, 0.1 mM EDTA, 0.05% Triton X-100 and freshly added 1 mM DTT, protease inhibitor cocktail (Sigma) and phosphatasee5 Cell 169, 203–215.e1–e8, April 6, 2017
inhibitor cocktails (Sigma). Nuclei were collected by centrifugation and the supernatant saved as the cytoplasmic fraction. Nuclei
were washed in buffer 2 (buffer 1 lacking detergent) and lysed as follows: Nuclear extracts for Western Blot were prepared in buffer
3 (500 mM NaCl, 50 mM Tris-HCl pH 8.0, 10% glycerol, 1% NP-40 and freshly added 1 mM DTT, protease inhibitor cocktail (Sigma)
and phosphatase inhibitor cocktails (Sigma)), sonicated and cleared from debris by high-speed centrifugation. For IP, nuclei were
lysed in buffer 4 (450 mM NaCl, 20 mM HEPES pH 7.5, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM EGTA, 10% glycerol, 0.3% Triton
X-100 and freshly added 1 mM DTT, protease inhibitor cocktail (Sigma) and phosphatase inhibitor cocktails (Sigma)), and cleared
from debris by high-speed centrifugation. Buffer 4 without the preceding fractionation steps was also used for preparation of whole
cell lysates. Prior to IP, salt and detergent concentrations in whole cell and nuclear extracts were adjusted to 150mMNaCl and 0.1%
Triton X-100, respectively. Lysates were pre-cleared with GammaBind G Sepharose (GE Healthcare) and incubated with primary
antibody against Cry1, Bmal1, Clock (all rabbit polyclonal, Bethyl Laboratories) or K538 Acetyl-Bmal1 (rabbit polyclonal, Millipore).
Rabbit polyclonal anti-Nfx1 antibody (Bethyl Laboratories) was used as isotype negative control. Immune complexes were precip-
itated with GammaBind G Sepharose (GE Healthcare), washed in buffer 5 (as IP buffer except with a higher detergent concentration
of 0.3% Triton X-100) and analyzed by SDS-PAGE and Western Blot. Western Blotting was performed according to standard pro-
cedures using the above described antibodies as well as anti-Per2 (rabbit polyclonal, Alpha Diagnostics) anti-TATA binding protein
TBP (mouse monoclonal, Abcam) and anti-a-Tubulin (mouse monoclonal, Sigma). Note on K538 Acetyl-Bmal1 antibody: Due to
differences in residue numbering between Bmal1 splice variants, K538 in the reference sequence used by the vendor (Uniprot
O00327-2) corresponds to the K537 residue for which acetylation has been described (Czarna et al., 2011; Hirayama et al., 2007).
Blots were quantified using ImageJ and statistical significance was tested using paired t tests in Prism 5 (GraphPad Software).
Clock Gene Expression Analysis
Total RNA was prepared from CRY1 fl or D11 MEFs using the RNeasy mini kit with on-column DNase digestion (QIAGEN). Equal
amounts of total RNAwere used for first-strand cDNA synthesis using the SuperScript III First-Strand Synthesis Systemwith random
hexamer priming followed by RNase H digestion (Invitrogen, Life Technologies). Diluted first-strand cDNA was used as template in
quantitative real-time PCR reactions using the LightCycler 480 SYBR Green I Master kit (Roche) and the oligos listed in Table S3.
Triplicate reactions for each sample and primer set were run on a LightCycler 480 instrument (Roche). Samples were quantified rela-
tive to a standard curve prepared from serial dilutions of concentrated cDNA run in parallel using the second derivative maximum
method in LightCycler 480 instrument software (version 1.5, Roche). Relative transcript levels were normalized to Tbp values and
expressed as fold change relative to the mean of the entire data series combining both genotypes. Statistical significance in
mean transcript expression levels between genotypes from five independent experiments was assessed by appropriate curve fitting
and comparing the best-fit-values between datasets by extra sum-of-squares F test in Prism 5 (GraphPadSoftware). For curve fitting,
a standard sine curve modified to allow for translation along the y axis (Y = Amplitude*sin((2*pi*X/Wavelength)+PhaseShift)+B) was
used for oscillating transcripts and a horizontal line (Y = Mean) was used for the non-circadian control transcript.
Chromatin Immunoprecipitation
For dual crosslinking, cells were treated with 2 mMEGS (Thermo Scientific) for 20min in PBS to which 1% Formaldehyde was added
for another 8 min. To stop the reaction, 156.25 mM glycine was added and incubation was continued for another 10 min. Cells were
washed in ice-cold PBS and lysed in cytoplasmic lysis buffer (320 mM sucrose, 10 mM Tris-HCl pH 8.0, 3 mM CaCl2, 2 mM Mg
Acetate, 0.1 mM EDTA, 0.5% NP-40). Nuclei were collected and washed as described above and dry pellets were stored
at 80C until further use. For chromatin immunoprecipitation (ChIP), nuclei were resuspended in ChIP lysis buffer (10 mM Tris-
HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.25% N-lauroylsarcosine and freshly added
protease inhibitor cocktail (Sigma)) and sonicated in a Bioruptor Pico (Diagenode) for 20 30 s cycles. Sonicated lysates were cleared
by high-speed centrifugation and an aliquot was removed and saved as the input sample. The remaining lysate was used undiluted
for CRY1 ChIP or diluted with ChIP buffer as follows: 1:3.33 for Bmal1 and Clock ChIP and 1:5 for H3K4me3 ChIP. Lysates were pre-
clearedwith Protein A/G Plus-agarose (Santa Cruz) that had been pre-blocked with 5mg/ml BSA. Pre-cleared lysates were incubated
with antibody overnight at 4C. Antibodies were as described above and Trimethyl-Histone H3 (Lys4) antibody was from Millipore.
Immune complexes were collected with Protein A/G agarose beads and washed three times in ChIP lysis buffer, three times in LiCl
wash buffer (20 mM Tris-HCl pH 7.5, 250 mM LiCl, 2 mM EDTA, 0.5% IGEPAL CA-630, 1% sodium deoxycholate, 1mM PMSF) and
once in TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA). Beads were incubated with elution buffer (20 mM Tris-HCl pH 8.0, 5 mM EDTA,
0.5% sodium dodecyl sulfate) for 30 min at 65C under agitation. ChIP eluates and saved input samples were reverse cross-linked
at 65C overnight and treated with 1 mg RNase (Roche) for 1 hr at 37C and 200 mg proteinase K (Roche) for 2 hr at 55C. DNA was
purified using commercial spin columns. The amount of Per2, Dbp and Lrwd1 promoter DNA in ChIP samples and 1/50-diluted input
samples was measured by quantitative real-time PCR as above using the oligos listed in Table S3. Triplicate reactions for each sam-
ple and primer set were run on a LightCycler 480 instrument (Roche) and quantified relative to a standard curve prepared from serial
dilutions of input DNA run in parallel. PCR results were adjusted for any applicable prior dilutions and results fromChIP samples were
normalized to the result of the respective input sample. For comparison between genotypes, results are expressed as fold change in
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Luciferase Repression Assay
Human CLOCK and ARNTL cDNAs were PCR amplified from first-strand cDNA libraries derived from human fibroblast cell lines and
blunt-cloned into the EcoRV-site of pBluescript. Sequences were confirmed by Sanger-sequencing.CLOCK and ARNTLORFs were
subcloned in frame into a modified pcDNA3.1 vector (Invitrogen, Life Technologies) containing an N-terminal Flag-tag using EcoRV/
NotI restriction sites.
293T cells were transiently transfected with 0.5 ng phRG-TK (renilla-luc, kind gift of S. Stanley), 5 ng pGL3-AVP (Kume et al., 1999),
125 ng pcDNA3-Flag-Clock, 125 ng pcDNA3-Flag-Bmal1 and 125 ng to 1 ng pcDNA3-HA-Cry1fl or D11 using Lipofectamin 2000
(Invitrogen, Life Technologies). DNA amounts were adjusted to a total of 500 ng per transfection with empty pcDNA3. Transcriptional
activity was assessed 48 hr post transfection by measuring the firefly/renilla luciferase ratio in cell lysates using a Dual-Luciferase
Reporter Assay System (Promega) and single tube luminometer (Berthold Detection Systems).
Cry DKO MEFs were transfected with 250 ng pGL3-Per2dLuc (Ueda et al., 2002) and 750 ng of lentiviral vectors pLV6puro-
hCry1fl, -D11, mCry2 or empty vector and transcriptional activity was assessed as above.
Luciferase Stability Assay
Vectors encoding C-terminal luciferase fusions of CRY1 fl and D11 (pcDNA3F-hCry1-luc) were generated by first cloning the respec-
tive open reading frames without the final stop codon into a modified pcDNA3.1 vector (Invitrogen, Life Technologies) containing an
N-terminal Flag-tag using EcoRV/NotI restriction sites. The luciferase ORF was amplified from pGL3 and cloned in frame into the
above CRY1 constructs using NotI/XbaI restriction sites. 293T cells were seeded in 35-mm plates and transfected with 1 mg
pcDNA3F-hCry1-luc (fl or D11) and 3 mg empty pcDNA3 vector using Lipofectamin 2000 (Invitrogen, Life Technologies). 48 hr after
transfection the medium was changed to counting medium (phenol red- and L-glutamine-free DMEM (GIBCO), 100 U/ml penicillin
and 100 mg/ml streptomycin, 10% FBS, 10 mM HEPES pH 7.2 (GIBCO), 2 mM L-glutamine (GIBCO), 0.5 mM firefly D-luciferin po-
tassium salt (Biosynth)). Cycloheximide was added to a final concentration of 20 mg/ml and luminescence was recorded every
15min in a LM-2400 bioluminescence detection system (Hamamatsu) for 24 hr. For analysis, raw luminescence datawere normalized
to the peak value of each sample and half-life was determined by fitting one-phase decay curves in Prism 5 (GraphPad Software).
QUANTIFICATION AND STATISTICAL ANALYSIS
Where applicable, statistical parameters including sample size, precision measures (standard error or standard deviation) and sta-
tistical significance are reported in the Figures and corresponding Figure Legends.
Data Analysis for Human In-Laboratory Study
For sleep data analysis, PSG TWin 4.1. software (Grass Technologies, Natus Neurology, West Warwick, RI) was used for scoring
electrographic recordings in 30 s epochs according to standard AASM criteria for N1, N2, N3, REM or wake. A list of sleep-stage/
wake status per epoch was created from the exported notations file of each scored record. Gaps within or between records were
treated as ‘wake’, if the laboratory technician log indicated that the subject was awake during this time. Any gaps occurring within
a sleep episode were regarded as sleep (without stage assignment) until indicated otherwise by the log. Analysis of circadian rhyth-
micity during the free-run was conducted using X2 periodogram and fast Fourier transform (FFT) functions on 2 min-binned data for
period and amplitude analyses, respectively, in ClockLab (ActiMetrics, Wilmette, IL).
For analysis of core body temperature data, raw data were corrected for non-physiological outliers associatedmostly with replace-
ment of the ingestible temperature sensor in the following way: Data were excluded, if they were outside of a lower or upper threshold
or if the difference between two adjacent points wasmore than 0.1C. Remaining outliers were removedmanually upon visual inspec-
tion of the temperature trace (see Figure S1). Data gapswere bridged by linear interpolation between the last and next available point.
Analysis of circadian rhythmicity during the free-runwas conducted in ClockLab (ActiMetrics,Wilmette, IL) on outlier-corrected, inter-
polated, 2 min-binned data. Period was derived from X2 periodogram. Data were mean-subtracted prior to determination of ampli-
tude by FFT.
Data Analysis for Whole Exome Sequencing
Sequences were aligned to human genome build GRCh37 using BWA (Burrows-Wheeler Aligner) (Li and Durbin, 2009). Duplicate
reads were marked using Picard (http://picard.sourceforge.net). GATK (Genome Analysis Toolkit) (DePristo et al., 2011) was used
for base quality score recalibration (BQSR) and local realignment around indels to refine alignment artifacts around putative insertions
or deletions. Variant discovery was performed in two steps - variant calling with GATK HaplotypeCaller followed by joint genotyping
using GATK GenotypeGVCFs. The resulting variant call set was refined using Variant Quality Score Recalibration (VQSR) as
implemented in GATK VariantRecalibrator. The VQSR scores were used to define low quality variants for downstream processing.
SnpEff (Cingolani et al., 2012) and VCFtools (Danecek et al., 2011) were used to add variant effect predictions and functional
annotations.
Potentially functional genetic variants co-segregating with the sleep phenotype were identified by WES of four affected and one
unaffected family member, as described above. After filtering, 33 candidate variants remained (Table S2). Of these variants, only
CRY1 c.1657+3A>C potentially affected a gene with a possible role in sleep or circadian rhythm. While not excluding the possibilitye7 Cell 169, 203–215.e1–e8, April 6, 2017
that a variant in a previously uncharacterized gene could be causal for the sleep phenotype, we decided first to carry out experimental
characterization of the CRY1 variant.
Cellular Period Analysis
Period analysis was performed by fitting a damped sine curve to time series data detrended by subtracting a running average using
Lumicycle analysis software (Actimetrics). Goodness-of-fit values for curve fitting were routinely above 90%. Statistical significance
between genotypes was assessed using an unpaired t test.
Association between CRY1 c.1657+3A>C Genotype and Sleep Behavior
Subjects were classified into the following behavioral categories: affected late, affected fragmented, probably affected, probably not
affected, not affected or uninterpretable. Factors that contributed to the classification of each subject are listed in Table S1. For the
statistical analysis of the association between sleep behavior and CRY1 allele status, the first three categories were combined as
‘affected’ and the third and fourth category were combined as ‘unaffected’. Subjects deemed ‘uninterpretable’ were excluded
from the analysis. Total subject numbers for the individual categories were as follows:Affected Non-affected Total
Carrier (C/C or +/C) 44 1 45
Non-carrier (+/+) 0 32 32
Total 44 33 77P value from Fisher’s exact test, odds ratio and 95% confidence interval were calculated in Prism 5 (GraphPad Software).
Analysis of Western Blot Data
Blots were quantified using ImageJ and statistical significance was tested using paired t tests in Prism 5 (GraphPad Software).
Analysis of Clock Gene Expression Data
Triplicate PCR reactions for each sample and primer set were run on a LightCycler 480 instrument (Roche). Samples were quantified
relative to a standard curve prepared from serial dilutions of concentrated cDNA run in parallel using the second derivative maximum
method in LightCycler 480 instrument software (version 1.5, Roche). Relative mRNA levels were normalized to Tbp values and ex-
pressed as fold change relative to the mean of the entire data series combining both genotypes. Statistical significance in mean tran-
script expression levels between genotypes from five independent experiments was assessed by appropriate curve fitting and
comparing the best-fit-values between datasets by extra sum-of-squares F test in Prism 5 (GraphPad Software). For curve fitting,
a standard sine curve modified to allow for translation along the y axis (Y = Amplitude*sin((2*pi*X/Wavelength)+PhaseShift)+B)
was used for oscillating transcripts and a horizontal line (Y = Mean) was used for the non-circadian control transcript.
Analysis of ChIP Data
Triplicate PCR reactions for each sample and primer set were run on a LightCycler 480 instrument (Roche) and quantified relative to a
standard curve prepared from serial dilutions of input DNA run in parallel. PCR results were adjusted for any applicable prior dilutions
(seeMethodDetails) and results fromChIP samples were normalized to the result of the corresponding input sample. For comparison
between genotypes, results are expressed as fold change in the CRY1 D11 sample compared to the CRY1 full-length sample, which
was set to 1. Average results from three independent experiments are shown.
DATA AND SOFTWARE AVAILABILITY
Further information and requests for raw data, analysis details, and DNA samples may be directed to and fulfilled in compliance with
IRB protocol requirements by Lead Contact Michael W. Young (young@rockefeller.edu), or for Turkish subjects by Tayfun Ozcelik
(tozcelik@bilkent.edu.tr). Whole exome sequencing data are not deposited in a public repository because the genetic sharing plans
of the IRB approved consent forms used in this study do not permit the deposition of such data into public or controlled-access
databases.Cell 169, 203–215.e1–e8, April 6, 2017 e8
Supplemental Figures
Control Subject TAU18 DSPD Subject TAU11
Figure S1. Core Body Temperature Rhythms of Control Subject TAU18 and the Proband TAU11, Related to Figure 2
Overlay of raw core body temperature readings (black dots) with outlier-corrected, interpolated data (red line). Sequential study days from entrainment day 1 (E1)










Figure S2. Double-Plotted Sleep Log Data of Proband Family Members TAUX01–03, Related to Figure 4 and Table S1
Red and blue triangles indicate in-bed/out-of-bed times, respectively. Black bars represent the self-estimated time asleep. Asterisks indicate Sundays. Upon
completion of sleep log 1, subjects TAUX01 and TAUX02 disclosed a necessity for early rising during the recorded period for reasons unrelated to the study and
indicated that data were not representative of their usual sleep-wake schedule. Subjects were therefore asked to repeat the data collection (sleep log 2). Data
from sleep log 1 are shown to illustrate features of abnormal sleep timing despite early wake times.
Figure S3. Effect of Exon 11 Deletion on CRY1 Function, Related to Figures 4 and 6
(A) Bmal-luc expression of Cry DKO MEFs reconstituted with lentiviral Cry2 and either empty vector or CRY1 fl or D11. All Cry forms were expressed using
regulatory elements previously characterized to recapitulate endogenous Cry1 oscillation (Ukai-Tadenuma et al., 2011). Cells were synchronized with 20 mM
forskolin and bioluminescence output was recorded for approximately seven days. Traces show detrended bioluminescence counts normalized to the first peak
for each genotype (Cry2 and vector control: gray, Cry2 and CRY1 fl: blue, Cry2 and CRY1 D11: red). Period for the latter two represents the average from
quadruplicate samples.
(B) Sequence comparison of the human and murine CRY1 tail. Identical residues are shaded in yellow. Preceding exon 11, murine Cry1 contains a 19-residue
insertion that is not present in human CRY1.
(C) Inhibition of Clock/Bmal1-dependend transcription by fl and D11 CRY1. An E-box-driven luciferase reporter plasmid AVP-luc was co-expressed in 293T cells
along with CLOCK, ARNTL and decreasing amounts of CRY1 fl orD11 as indicated. Data represent the mean induction of bioluminescence over basal levels from
duplicate transfections at 48 hr post-transfection. Error bars represent the standard deviation from duplicate samples.
(D) Transcriptional inhibition in Cry DKO cells transiently transfected with Per2-dLuc and either empty vector or a lentiviral vector encoding CRY1 fl, CRY1 D11 or
Cry2 under control of a physiological Cry1 promoter (Khan et al., 2012). Data represent the mean induction of bioluminescence from quadruplicate transfections
at 48 hr post-transfection. Error bars represent the standard deviation from quadruplicate samples.
(E) Protein stability of CRY1 fl and D11. Proband fibroblasts were treated with 20 mg/ml cycloheximide (CHX) for the indicated times or with solvent control. CRY1
levels were measured by Western Blot in fractionated cytoplasmic and nuclear extracts with TUBULIN and TBP used as controls for protein loading and frac-
tionation purity.
(F) Luciferase fusion proteins of fl and D11 CRY1 were transiently expressed in 293T cells. Cells were treated with 20 mg/ml CHX and luminescence was recorded
over time. For analysis, raw luminescence data were normalized to the peak value of each sample and half-life was determined by fitting one-phase decay curves
in Prism 5 (GraphPad Software). Error bars represent the standard error from quadruplicate samples.
Figure S4. Effect of Exon 11 Deletion on CRY1 Function, Related to Figure 6
(A–E) Quantification of findings reported in Figure 6. Plotted data include exact experiments from Figure 6 as well as independent replications. Individual panels
combine data derived from both synchronized and unsynchronized cells and, for (C–E), immunoprecipitations performed on whole cell and nuclear extracts.
Sample size and statistical significance as determined by paired t test are included in each panel. (A) Ratio of CRY1 full-length to CRY1 D11 expression in
cytoplasmic versus nuclear extracts from TAU11 fibroblasts. (B) Ratio of CRY1 full-length to CRY1 D11 expression in cytoplasmic versus nuclear extracts from
CRY1 fl/DMEFs. (C) Ratio of CRY1 full-length to CRY1 D11 co-immunoprecipitating with CLOCK or ARNTL compared to the lysate input prepared from TAU11
fibroblasts. (D) Ratio of CRY1 full-length to CRY1 D11 co-immunoprecipitating with Clock, Bmal1 or Acetyl-Bmal1 compared to the lysate input prepared from
CRY1 fl/D MEFs. (E) Full-length or D11 CRY1 were immunoprecipitated from MEFs expressing either CRY1 form. Data show the fold change in the CRY1 D11
sample over the CRY1 full-length sample for CRY1 and co-immunoprecipitating Clock, Bmal1, Acetyl-Bmal1 and Per2.
Figure S5. Mechanism of Circadian Clock Regulation by CRY1 D11, Related to Figures 6 and 7
Deletion of exon 11 leads to enhancedCRY1 nuclear localization, interaction with transcription factors Clock/Bmal1, their displacement fromDNA and repression
of target genes.
